At a glance
ClinicalIndex Comparison Record- ✓Age 40–70 years
- ✓Non-smoker
- ✓At moderate cardiovascular risk (QRISK2 10–20%)
- ✓Risk assessment via QRISK2 calculator scoring 10–20% for 10-year cardiovascular event risk
- ✕BMI <18.5 kg/m²
- ✕Anaemia: haemoglobin <12.5 g/L (men) or <11.5 g/L (women)
- ✕Hyperlipidaemia: total cholesterol >8 mmol/L
- ✕Diabetes or fasting glucose >7 mmol/L
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Fish Oil-derived N-3 Polyunsaturated Fatty Acids on the Generation and Functional Activities of Extracellular Vesicles
In Brief
A clinical study evaluating Fish oil capsules and High-oleic safflower oil capsules for Extracellular Vesicles; Generation and Function. Completed, enrolled 42 participants across 1 site.
Detailed Summary
N-3 polyunsaturated fatty acids (n-3 PUFA), which are abundant in oily fish and fish oils, have been suggested to play a role in reducing the risk of cardiovascular diseases (CVDs) by modifying a wide range of risk factors, such as blood fats, blood clotting, blood vessel function and inflammation. Extracellular vesicles (EVs) are small particles released from various cells when they are activated or damaged. High numbers of EVs in the blood have been associated with a higher risk of CVDs, and it is thought that this is because they carry 'bioactive' components which can affect many processes involved in CVDs. However, very few clinical trials have investigated the relationships between the consumption of n-3 PUFA and circulating EVs. This study aims to investigate the effects of dietary n-3 PUFA on the generation and functional activities of EVs, which would provide new insight into the benefits of n-3 PUFA on cardiovascular health.
Study Details
Timeline
Interventions
Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
High-oleic safflower oil capsules for 12 weeks